Archives of neurology Journal

Overview
Identity
View All

publication venue for

Regional white matter hyperintensity volume, not hippocampal atrophy, predicts incident Alzheimer disease in the community.. 69:1621-7. 2012
Comprehensive search for Alzheimer disease susceptibility loci in the APOE region.. 69:1270-9. 2012
Diabetes, glucose control, and 9-year cognitive decline among older adults without dementia.. 69:1170-5. 2012
Amyloid-β--associated clinical decline occurs only in the presence of elevated P-tau.. 69:709-13. 2012
11C-PiB imaging of human immunodeficiency virus-associated neurocognitive disorder.. 69:72-7. 2012
Age, statin use, and the risk for incident Parkinson disease-reply.. 69:-. 2012
CSF biomarkers for secondary prevention trials: why markers of amyloid deposition and neurodegeneration are both important.. 69:691-2. 2012
Characterization of a family with c9FTD/ALS associated with the GGGGCC repeat expansion in C9ORF72.. 69:1164-9. 2012
Exercise Engagement as a Moderator of the Effects of APOE Genotype on Amyloid Deposition.. 69:636-43. 2012
Incidence of new-onset seizures in mild to moderate Alzheimer disease.. 69:368-72. 2012
Pathologic accumulation of α-synuclein and Aβ in Parkinson disease patients with dementia.. 69:1326-31. 2012
Prospective study of statin use and risk of Parkinson disease.. 69:380-4. 2012
Reduced uptake of FDOPA PET in end-stage liver disease with elevated manganese levels.. 69:394-7. 2012
Shapes of the trajectories of 5 major biomarkers of Alzheimer disease.. 69:856-67. 2012
To sleep, perchance to delay dementia.. 69:118-20. 2012
Status epilepticus-induced hyperemia and brain tissue hypoxia after cardiac arrest.. 68:1323-6. 2011
The dynamics of cortical and hippocampal atrophy in Alzheimer disease.. 68:1040-8. 2011
Mild cognitive impairment, dementia, and their subtypes in oldest old women.. 68:631-6. 2011
Telephone-based identification of mild cognitive impairment and dementia in a multicultural cohort.. 68:607-14. 2011
Test-retest reliability of memory task functional magnetic resonance imaging in Alzheimer disease clinical trials.. 68:599-606. 2011
Association and expression analyses with single-nucleotide polymorphisms in TOMM40 in Alzheimer disease.. 68:1013-9. 2011
Cerebrospinal fluid biomarkers, education, brain volume, and future cognition.. 68:1145-51. 2011
Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology.. 68:1137-44. 2011
Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative.. 67:1370-8. 2010
Plasma ß-amyloid and cognitive decline.. 67:1485-90. 2010
Defining successful aging: the importance of including cognitive function over time.. 67:876-80. 2010
Food combination and Alzheimer disease risk: a protective diet.. 67:699-706. 2010
Cerebrovascular carbon dioxide reactivity and delayed cerebral ischemia after subarachnoid hemorrhage.. 67:434-9. 2010
Quantitative template for subtyping primary progressive aphasia.. 66:1545-51. 2009
Promising strategies for the prevention of dementia.. 66:1210-5. 2009
Extrapyramidal signs before and after diagnosis of incident Alzheimer disease in a prospective population study.. 66:1120-6. 2009
Seizures in Alzheimer disease: who, when, and how common?. 66:992-7. 2009
Contribution of vascular risk factors to the progression in Alzheimer disease.. 66:343-8. 2009
The metabolic syndrome and development of cognitive impairment among older women.. 66:324-8. 2009
Total and regional adiposity and cognitive change in older adults: The Health, Aging and Body Composition (ABC) study.. 66:329-35. 2009
Mediterranean diet and mild cognitive impairment.. 66:216-25. 2009
Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report.. 66:1557-62. 2009
Cerebrospinal fluid beta-amyloid 42, Tau, and P-tau: confirmation now realization.. 66:1552-3. 2009
Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type.. 66:638-45. 2009
Codistribution of amyloid beta plaques and spongiform degeneration in familial Creutzfeldt-Jakob disease with the E200K-129M haplotype.. 66:1240-6. 2009
Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease.. 66:1469-75. 2009
Urate as a predictor of the rate of clinical decline in Parkinson disease.. 66:1460-8. 2009
Measuring cerebral atrophy and white matter hyperintensity burden to predict the rate of cognitive decline in Alzheimer disease.. 65:1202-8. 2008
Distinct pools of beta-amyloid in Alzheimer disease-affected brain: a clinicopathologic study.. 65:906-12. 2008
Increased frequency of learning disability in patients with primary progressive aphasia and their first-degree relatives.. 65:244-8. 2008
Nutritional support after ischemic stroke: more food for thought.. 65:15-6. 2008
Serum urate as a predictor of clinical and radiographic progression in Parkinson disease.. 65:716-23. 2008
Disruptive behavior as a predictor in Alzheimer disease.. 64:1755-61. 2007
Leisure activity and cognitive decline in incident Alzheimer disease.. 64:1749-54. 2007
Three-dimensional gray matter atrophy mapping in mild cognitive impairment and mild Alzheimer disease.. 64:1489-95. 2007
The association between genetic variants in SORL1 and Alzheimer disease in an urban, multiethnic, community-based cohort.. 64:501-6. 2007
An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection.. 64:97-102. 2007
Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.. 64:343-9. 2007
Pittsburgh compound B retention and verification of amyloid deposition.. 64:315-6. 2007
Expanded genomewide scan implicates a novel locus at 3q28 among Caribbean hispanics with familial Alzheimer disease.. 63:1591-8. 2006
Mediterranean diet, Alzheimer disease, and vascular mediation.. 63:1709-17. 2006
The progression of cognition, psychiatric symptoms, and functional abilities in dementia with Lewy bodies and Alzheimer disease.. 63:1450-6. 2006
Effects of ultra-low-dose transdermal estradiol on cognition and health-related quality of life.. 63:945-50. 2006
Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps.. 63:693-9. 2006
An observational study of cognitive impairment in amyotrophic lateral sclerosis.. 63:345-52. 2006
Relation of quantitative indexes of concurrent alpha-synuclein abnormalities to clinical outcome in autopsy-proven Alzheimer disease.. 63:226-30. 2006
Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men.. 63:177-85. 2005
Implementing diagnostic criteria and estimating frequency of mild cognitive impairment in an urban community.. 62:1739-46. 2005
Delusions and hallucinations are associated with worse outcome in Alzheimer disease.. 62:1601-8. 2005
Deep white matter pathologic features in watershed regions: a novel pattern of central nervous system involvement in MELAS.. 62:1154-6. 2005
Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment.. 62:975-80. 2005
Bone mineral density and the risk of Alzheimer disease.. 62:107-11. 2005
Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy.. 61:1687-96. 2004
APOE and APOC1 promoter polymorphisms and the risk of Alzheimer disease in African American and Caribbean Hispanic individuals.. 61:1434-9. 2004
Cognitive reserve-mediated modulation of positron emission tomographic activations during memory tasks in Alzheimer disease.. 61:73-8. 2004
Stroke and the risk of Alzheimer disease.. 60:1707-12. 2003
The rate of cognitive decline and risk of reaching clinical milestones in Alzheimer disease.. 60:1137-42. 2003
Screening for mutations in the MECP2 (Rett syndrome) gene in Gilles de la Tourette syndrome.. 60:502-3. 2003
Association of life activities with cerebral blood flow in Alzheimer disease: implications for the cognitive reserve hypothesis.. 60:359-65. 2003
Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease.. 60:1059-64. 2003
Cognitive and physiologic correlates of subclinical structural brain disease in elderly healthy control subjects.. 59:1612-20. 2002
Longitudinal assessment of patient dependence in Alzheimer disease.. 59:1304-8. 2002
Friedreich ataxia: effects of genetic understanding on clinical evaluation and therapy.. 59:743-7. 2002
Serum lipoprotein levels, statin use, and cognitive function in older women.. 59:378-84. 2002
A controlled prospective study of neuropsychological dysfunction following carotid endarterectomy.. 59:217-22. 2002
Familial Alzheimer disease among Caribbean Hispanics: a reexamination of its association with APOE.. 59:87-91. 2002
An investigation of clinical correlates of Lewy bodies in autopsy-proven Alzheimer disease.. 58:460-5. 2001
Factors associated with incident human immunodeficiency virus-dementia.. 58:473-9. 2001
Regional magnetic resonance imaging lesion burden and cognitive function in multiple sclerosis: a longitudinal study.. 58:115-21. 2001
Amyotrophy in prion diseases.. 57:33-8. 2000
Donepezil therapy in clinical practice: a randomized crossover study.. 57:94-9. 2000
Familial aggregation of Alzheimer disease among whites, African Americans, and Caribbean Hispanics in northern Manhattan.. 57:72-7. 2000
A clinicopathological comparison of community-based and clinic-based cohorts of patients with dementia.. 56:1368-73. 1999
The effect of patient attrition on estimates of the frequency of dementia following stroke.. 55:390-4. 1998
The validity of new memory complaints in the elderly.. 54:756-9. 1997
Modeling the influence of extrapyramidal signs on the progression of Alzheimer disease.. 53:1121-6. 1996
A comparison of cerebral SPECT abnormalities in HIV-positive homosexual men with and without cognitive impairment.. 52:1170-3. 1995
Cerebral single-photon emission computed tomography abnormalities in human immunodeficiency virus type 1-infected gay men without cognitive impairment.. 52:607-11. 1995
Clinical correlates of Alzheimer's disease with and without silent radiographic abnormalities.. 52:146-51. 1995
Neuropsychologic impairment in early HIV infection. A risk factor for work disability.. 52:525-30. 1995
Risk of human immunodeficiency virus type 1-related neurologic disease in a cohort of intravenous drug users.. 52:1174-82. 1995
Serum neopterin level predicts HIV-related mortality but not progression to AIDS or development of neurological disease in gay men and parenteral drug users.. 52:676-9. 1995
The frequency and associated risk factors for dementia in patients with Parkinson's disease.. 52:695-701. 1995
Risk factors for the neurologic complications associated with aortic aneurysms.. 49:284-8. 1992